143 related articles for article (PubMed ID: 38115904)
1. Case Report: Lenvatinib for the treatment of recurrent hepatocellular carcinoma in people living with HIV: a report of two cases.
Morsica G; Bertoni C; Hasson H; Messina E; Uberti Foppa C
Front Oncol; 2023; 13():1242741. PubMed ID: 38115904
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Living Donor Liver Transplantation: A Report of Two Cases.
Ichida A; Akamatsu N; Nagata R; Mihara Y; Kawaguchi Y; Bae SK; Ishizawa T; Kaneko J; Arita J; Hasegawa K
Anticancer Res; 2022 Feb; 42(2):1161-1167. PubMed ID: 35093921
[TBL] [Abstract][Full Text] [Related]
3. Well-controlled viremia reduces the progression of hepatocellular carcinoma in chronic viral hepatitis patients treated with lenvatinib.
Hsiao YW; Sou FM; Wang JH; Chen YH; Tsai MC; Hu TH; Hung CH; Chen CH; Kuo YH
Kaohsiung J Med Sci; 2023 Dec; 39(12):1233-1242. PubMed ID: 37843189
[TBL] [Abstract][Full Text] [Related]
4. Recurrent hepatogastric fistula during lenvatinib therapy for advanced hepatocellular carcinoma managed by over-the-scope clip closure: a case report.
Miwa T; Kochi T; Watanabe K; Hanai T; Imai K; Suetsugu A; Takai K; Shiraki M; Katsumura N; Shimizu M
J Rural Med; 2021 Apr; 16(2):102-110. PubMed ID: 33833836
[No Abstract] [Full Text] [Related]
5. Downstaging of Recurrent Advanced Hepatocellular Carcinoma After Lenvatinib Treatment: Opportunities or Pitfalls? A Case Report.
Liu Z; Fu Z; Li G; Lin D
Onco Targets Ther; 2020; 13():10267-10273. PubMed ID: 33116607
[TBL] [Abstract][Full Text] [Related]
6. Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report.
Yokoo H; Takahashi H; Hagiwara M; Iwata H; Imai K; Saito Y; Matsuno N; Furukawa H
World J Hepatol; 2020 Dec; 12(12):1349-1357. PubMed ID: 33442460
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study.
Chen YY; Chen CL; Lin CC; Wang CC; Liu YW; Li WF; Chen YH
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572811
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study.
Zhao L; Chang N; Shi L; Li F; Meng F; Xie X; Xu Z; Wang F
Heliyon; 2022 Jun; 8(6):e09538. PubMed ID: 35706954
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma.
Xin Y; Zhang X; Liu N; Peng G; Huang X; Cao X; Zhou X; Li X
Hepatol Int; 2023 Jun; 17(3):753-764. PubMed ID: 37038024
[TBL] [Abstract][Full Text] [Related]
11. Potential Role of Adjuvant Lenvatinib in Improving Disease-Free Survival for Patients With High-Risk Hepatitis B Virus-Related Hepatocellular Carcinoma Following Liver Transplantation: A Retrospective, Case Control Study.
Han B; Ding H; Zhao S; Zhang Y; Wang J; Zhang Y; Gu J
Front Oncol; 2020; 10():562103. PubMed ID: 33365268
[TBL] [Abstract][Full Text] [Related]
12. A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk.
Kosaka Y; Kawaoka T; Aikata H; Suehiro Y; Yamaoka K; Ando Y; Namba M; Takeuchi Y; Fujii Y; Uchikawa S; Kodama K; Oya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Baba Y; Awai K; Kimura T; Nagata Y; Chayama K
Clin J Gastroenterol; 2020 Oct; 13(5):839-843. PubMed ID: 31974811
[TBL] [Abstract][Full Text] [Related]
13. Subsequent locoregional therapy prolongs survival in progressive hepatocellular carcinoma patients under lenvatinib treatment.
Lin PT; Teng W; Jeng WJ; Lin CC; Lin CY; Lin SM; Sheen IS
J Formos Med Assoc; 2024 Feb; ():. PubMed ID: 38310071
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation.
Park MK; Lee YB; Moon H; Choi NR; Kim MA; Jang H; Nam JY; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yoon JH
Dig Dis Sci; 2022 Oct; 67(10):4939-4949. PubMed ID: 35048224
[TBL] [Abstract][Full Text] [Related]
15. A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario.
Dipasquale A; Marinello A; Santoro A
J Hepatocell Carcinoma; 2021; 8():241-251. PubMed ID: 33884259
[TBL] [Abstract][Full Text] [Related]
16. Long-term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion.
Takeda H; Nishijima N; Nasu A; Komekado H; Kita R; Kimura T; Kudo M; Osaki Y
Hepatol Res; 2019 May; 49(5):594-599. PubMed ID: 30499247
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation.
Bang K; Casadei-Gardini A; Yoo C; Iavarone M; Ryu MH; Park SR; Kim HD; Yoon YI; Jung DH; Park GC; Ahn CS; Moon DB; Hwang S; Kim KH; Song GW; Mazzarelli C; Alimenti E; Chan SL; De Giorgio M; Ryoo BY; Lee SG
Cancer Med; 2023 Feb; 12(3):2572-2579. PubMed ID: 36812124
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of lenvatinib for preventing tumor recurrence after liver transplantation in hepatocellular carcinoma beyond the Milan criteria.
Guo DZ; Cheng JW; Yan JY; Huang A; Wang YP; Zhang SY; Cao Y; Huang XW; Fan J; Zhou J; Yang XR
Ann Transl Med; 2022 Oct; 10(20):1091. PubMed ID: 36388794
[TBL] [Abstract][Full Text] [Related]
19. A case of complete response with rechallenge-lenvatinib plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma refractory to multiple molecular-targeted agent treatments.
Tomonari T; Tanaka H; Tanaka T; Taniguchi T; Sogabe M; Kawano Y; Okamoto K; Miyamoto H; Sato Y; Takayama T
Clin J Gastroenterol; 2023 Jun; 16(3):438-443. PubMed ID: 36856957
[TBL] [Abstract][Full Text] [Related]
20. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
